AI Article Synopsis
Article Abstract
The objective of our study was to profile and compare the systematic changes between orally administered artesunate and intramuscularly injected artemether at a low dose over a 3-month period (92 consecutive days) in dogs. Intramuscular administration of 6 mg kg-1 artemether induced a decreased red blood cell (RBC) count (anemia), concurrent extramedullary hematopoiesis in the spleen and inhibition of erythropoiesis in the bone marrow. We also observed a prolonged QT interval and neuropathic changes in the central nervous system, which demonstrated the cortex and motor neuron vulnerability, but no behavioral changes. Following treatment with artesunate, we observed a decreased heart rate, which was most likely due to cardiac conduction system damage, as well as a deceased RBC count, extramedullary hematopoiesis in the spleen and inhibition of erythropoiesis in the bone marrow. However, in contrast to treatment with artemether, neurotoxicity was not observed following treatment with artesunate. In addition, ultra-structural examination by transmission electron microscopy showed mitochondrial damage following treatment with artesunate. These findings demonstrated the spectrum of toxic changes that result upon treatment with artesunate and artemether and show that the prolonged administration of low doses of these derivatives result in diverse toxicity profiles.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989207 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094034 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Pyrexia of Foreign Origin: Exploring the Impact of Travel History.
Cureus
November 2024
Internal Medicine, Portsmouth Hospitals University, Portsmouth, GBR.
Malaria remains a significant global health challenge, particularly in endemic regions of Africa, with being the most virulent species. This case report details the presentation of a 24-year-old Caucasian woman who collapsed at a train station in the United Kingdom after experiencing a week of fever, malaise, abdominal pain, and gastrointestinal symptoms. At emergency care, she was initially resuscitated with intravenous fluids and antipyretics.
View Article and Find Full Text PDF[Research progress on artemisinin and its derivatives in treatment of orthopedics-related diseases].
Zhongguo Zhong Yao Za Zhi
September 2024
Tianjin Hospital, Tianjin University (Tianjin Hospital) Tianjin 300211, China Tianjin Institute of Orthopedics Tianjin 300050, China Tianjin Key Laboratory of Orthopedic Biomechanics and Medical Engineering Tianjin 300050, China.
As research into the mechanisms of orthopedic diseases continues to deepen, the shortcomings of traditional single-target the-rapies are becoming increasingly apparent. Consequently, the search for multi-target drugs has become the mainstream research direction for orthopedics-related diseases. Artemisinin, a sesquiterpene lactone compound extracted from Artemisia annua, has led to the gradual synthesis of various derivatives such as dihydroartemisinin, artesunate, artemether, and arteether.
View Article and Find Full Text PDFArtemether-lumefantrine-amodiaquine or artesunate-amodiaquine combined with single low-dose primaquine to reduce Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a five-arm, phase 2, single-blind, randomised controlled trial.
Lancet Microbe
December 2024
Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Background: Triple artemisinin-based combination therapies (TACTs) can delay the spread of antimalarial drug resistance. Artesunate-amodiaquine is widely used for uncomplicated Plasmodium falciparum malaria. We therefore aimed to determine the safety and efficacy of artemether-lumefantrine-amodiaquine and artesunate-amodiaquine with and without single low-dose primaquine for reducing gametocyte carriage and transmission to mosquitoes.
View Article and Find Full Text PDFEfficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with infection: open-label, randomized, head-to-head, non-inferiority trial.
Antimicrob Agents Chemother
December 2024
Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance. We compared the efficacy and safety of praziquantel combined with four different artemisinin-based combinations to praziquantel alone in treating infection in Kenyan children. In this randomized, open-label, five-arm, head-to-head, non-inferiority trial, children (aged 9-15 years) with infection according to duplicate Kato Katz thick smears from a stool sample in the Mwea irrigation scheme of central Kenya, were enrolled.
View Article and Find Full Text PDFEvaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials.
Malar J
December 2024
Groupe de Recherche Action en Santé (GRAS), Ouagadougou, West Africa, Burkina Faso.
Background: In malaria vaccine clinical trials, immune responses after vaccination may be compromised due to immunosuppression caused by concurrent Plasmodium falciparum infection. This has a direct effect on the protective efficacy of the vaccine being evaluated. Therefore, parasite clearance prior to vaccination is being considered.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!